Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06690138 · ClinicalTrials.gov registry record · Phase 1

A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy Participants

A Phase 1 study, sponsored by Genentech.

Completed
Registry status
Phase 1
Development phase
18
Enrollment target

NCT06690138: Completed Phase 1 study, sponsored by Genentech.

NCT06690138 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06690138, a Phase 1 study, has completed, sponsored by Genentech.

COMPLETED
Registry status
Phase 1
Development phase
18 participants
Enrollment target

Study Summary

This is a Phase 1, open-label, two-period, fixed sequence drug-drug interaction study to evaluate the impact of multiple doses of Itraconazole on the pharmacokinetics (PK) and safety of Divarasib in healthy participants.

Interventions

  • DRUG Divarasib
  • DRUG Itraconazole

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2024-11-15
Est. Completion 2025-02-11
Phase Phase 1
Genentech

332 total trials

What the finished NCT06690138 record still lists

NCT06690138 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).

The record links to 0 conditions, and to 2 interventions - of which Divarasib is the first listed.

NCT06690138 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06690138 about?

NCT06690138 is a clinical study titled "A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy Participants". This is a Phase 1, open-label, two-period, fixed sequence drug-drug interaction study to evaluate the impact of multiple doses of Itraconazole on the pharmacokinetics (PK) and safety of Divarasib in healthy participants.

What is the current status of trial NCT06690138?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2024-11-15. Estimated completion is 2025-02-11.

What interventions are being tested in trial NCT06690138?

The interventions under investigation include: Divarasib (DRUG), Itraconazole (DRUG).

Who is sponsoring clinical trial NCT06690138?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06690138's enrollment target sits among peer trials

18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06690138, the US trial registry maintained by the National Library of Medicine. NCT06690138 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.